Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
CalciMedica is a clinical-stage biopharmaceutical company developing innovative therapeutics targeting calcium release-activated calcium (CRAC) channels. Its lead product, Auxora, is a selective IV CRAC channel inhibitor aimed at treating acute critical illnesses such as pancreatitis, kidney injury, and respiratory failure. The company's dual anti-inflammatory and tissue-protective approach addresses unmet needs in severe inflammatory and immunologic diseases across acute and chronic markets.
This description was generated via AI from an annual report. Updated about 1 year ago.